While this happened, ROTH MKM initiated its Reviva Pharmaceuticals Holdings Inc [RVPH] rating to a Buy in a research note published on September 20, 2023; the price target was $12. A number of analysts have revised their coverage, including The Benchmark Company’s analysts, who began to cover the stock in early June with a ‘”a Speculative buy”‘ rating. H.C. Wainwright began covering RVPH with “Buy” recommendation on January 24, 2022.
Price Performance Review of RVPH
On Tuesday, Reviva Pharmaceuticals Holdings Inc [NASDAQ:RVPH] saw its stock jump 1.52% to $2.00. Over the last five days, the stock has gained 10.50%. Reviva Pharmaceuticals Holdings Inc shares have risen nearly 10.50% since the year began. Nevertheless, the stocks have fallen -61.46% over the past one year. While a 52-week high of $5.21 was reached on 01/07/25, a 52-week low of $0.60 was recorded on 01/02/25. SMA at 50 days reached $1.4900, while 200 days put it at $1.6400.
Levels Of Support And Resistance For RVPH Stock
The 24-hour chart illustrates a support level at 1.8200, which if violated will result in even more drops to 1.6300. On the upside, there is a resistance level at 2.1800. A further resistance level may holdings at 2.3500. The Relative Strength Index (RSI) on the 14-day chart is 57.04, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.2200, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 18.09%. Stochastics %K at 56.62% indicates the stock is a holding.
How much short interest is there in Reviva Pharmaceuticals Holdings Inc?
A steep rise in short interest was recorded in Reviva Pharmaceuticals Holdings Inc stocks on 2024-10-31, dropping by -0.17 million shares to a total of 5.3 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 5.47 million shares. There was a decline of -3.21%, which implies that there is a negative sentiment for the stock.
